NASDAQ:BIOC - Nasdaq - US09072V6002 - Common Stock - Currency: USD
BIOC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. BIOC has a bad profitability rating. Also its financial health evaluation is rather negative. BIOC has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -239.73% | ||
ROE | -18271.38% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 4.7 | ||
Debt/FCF | N/A | ||
Altman-Z | -26.33 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.81 | ||
Quick Ratio | 1.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.4349
-0.07 (-13.05%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.04 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.61 | ||
P/tB | 3.61 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -239.73% | ||
ROE | -18271.38% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 4.7 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 37.18% | ||
Cap/Sales | 2.42% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.81 | ||
Quick Ratio | 1.7 | ||
Altman-Z | -26.33 |